Education
About Us
Working with TipRanks
Follow Us
FFOX - ETF AI Analysis
Top Page
FundX Future Fund Opportunities ETF (FFOX)
Rating:59Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid gains so far this year, reflecting positive momentum in its holdings.
Sector Diversification
The fund is spread across multiple sectors, including Technology, Health Care, and Industrials, reducing reliance on any single industry.
Healthy Top Holdings
Several top holdings, such as Guardant Health and Ionis Pharmaceuticals, have shown strong year-to-date performance, contributing to the fund’s success.
Negative Factors
High Expense Ratio
The ETF charges a relatively high expense ratio, which could eat into investor returns over time.
Geographic Concentration
The fund is heavily concentrated in U.S. companies, limiting exposure to international markets and diversification.
Underperforming Holdings
Some holdings, like Globus Medical and Penumbra, have shown weaker year-to-date performance, which may drag on overall returns.
FFOX vs. SPDR S&P 500 ETF (SPY)
AUM192.73M
RegionNorth America
Expense Ratio1.00%
Beta0.93
IssuerFundX
Inception DateJun 10, 2025
Dividend Yield1.73%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume15,396
30 Day Avg. Volume16,997
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
32.87Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering81
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FFOX Summary
The FundX Future Fund Opportunities ETF (FFOX) is an actively managed fund that invests in small- and mid-sized companies benefiting from major global trends like technology, sustainability, and demographic changes. It includes companies such as Guardant Health and Ionis Pharmaceuticals, focusing on sectors like technology and healthcare. This ETF offers a way to invest in innovative industries with potential for long-term growth. However, new investors should know that its performance can be volatile since it targets smaller companies and specific themes, which may be more sensitive to market changes.
How much will it cost me?The FundX Future Fund Opportunities ETF (FFOX) has an expense ratio of 1.00%, meaning you’ll pay $10 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on identifying and investing in sectors aligned with transformative global trends.
What would affect this ETF?FFOX's focus on transformative megatrends like technology and healthcare positions it to benefit from advancements in innovation and demographic shifts, which could drive long-term growth. However, its exposure to small- and mid-cap companies may make it more sensitive to economic downturns or interest rate hikes, which can negatively impact these sectors. Additionally, regulatory changes in healthcare or technology could pose risks to its top holdings.
FFOX Top 10 Holdings
The FundX Future Fund Opportunities ETF (FFOX) leans heavily into technology and healthcare, with these sectors driving much of its performance. Penumbra and Globus Medical are rising stars, benefiting from strong financial results and strategic growth initiatives, though caution is warranted due to valuation concerns. Guardant Health and Ionis Pharmaceuticals are lagging slightly, held back by profitability challenges despite promising product launches. With a clear focus on U.S.-based small- and mid-cap companies aligned with transformative trends, FFOX offers a thematic play on innovation, though its concentrated sector exposure may amplify volatility.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ― | 7.28% | $13.97M | ― | ― | ― | |
| ― | 4.86% | $9.33M | ― | ― | ― | |
| Guardant Health | 2.12% | $4.06M | $14.22B | 197.18% | 61 Neutral | |
| Ionis Pharmaceuticals | 1.99% | $3.83M | $13.47B | 139.12% | 61 Neutral | |
| Globus Medical | 1.94% | $3.73M | $12.19B | 9.32% | 82 Outperform | |
| Penumbra | 1.92% | $3.69M | $12.38B | 22.39% | 78 Outperform | |
| TechnipFMC | 1.90% | $3.64M | $19.89B | 51.89% | 80 Outperform | |
| Natera | 1.77% | $3.39M | $35.19B | 35.64% | 73 Outperform | |
| Halozyme | 1.76% | $3.37M | $8.83B | 34.17% | 73 Outperform | |
| Millicom International Cellular SA | 1.68% | $3.23M | $8.55B | 109.08% | 71 Outperform |
FFOX Technical Analysis
Positive
―
Price Trends
27.85
Positive
27.65
Positive
Market Momentum
0.12
Negative
57.50
Neutral
96.69
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FFOX, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 28.16, equal to the 50-day MA of 27.85, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.12 indicates Negative momentum. The RSI at 57.50 is Neutral, neither overbought nor oversold. The STOCH value of 96.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FFOX.
FFOX Peer Comparison
Comparison Results
Performance Comparison
FFOX
FundX Future Fund Opportunities ETF
28.58
3.39
13.46%
PWRD
Tcw Transform Systems Etf
―
―
―
FEPI
REX FANG & Innovation Equity Premium Income ETF
―
―
―
SAMT
Strategas Macro Thematic Opportunities ETF
―
―
―
DUNK
Dana Unconstrained Equity ETF
―
―
―
TPZ
Tortoise Essential Energy Fund
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents